Amerise Biosciences Limited (BOM:531681)
India
· Delayed Price · Currency is INR 0.660
+0.060 (10.00%)
At close: Mar 9, 2026
Amerise Biosciences Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | - | 0.22 | 0.21 | 0.14 | 0.13 | 0.19 | Upgrade
|
| Cash & Short-Term Investments | 0.24 | 0.22 | 0.21 | 0.14 | 0.13 | 0.19 | Upgrade
|
| Cash Growth | 49.06% | 5.21% | 55.15% | 4.61% | -32.69% | -23.13% | Upgrade
|
| Accounts Receivable | - | - | - | - | 62.17 | - | Upgrade
|
| Receivables | - | - | - | - | 62.17 | - | Upgrade
|
| Other Current Assets | - | 0.05 | 0.02 | - | -0 | - | Upgrade
|
| Total Current Assets | - | 0.27 | 0.23 | 0.14 | 62.29 | 0.19 | Upgrade
|
| Long-Term Investments | - | 23.81 | 22.65 | 45.66 | 46.91 | 30.41 | Upgrade
|
| Other Long-Term Assets | - | - | - | - | -0 | - | Upgrade
|
| Total Assets | - | 84.63 | 53.9 | 56.47 | 119.88 | 56.28 | Upgrade
|
| Accounts Payable | - | - | - | - | 62.66 | 4.8 | Upgrade
|
| Current Income Taxes Payable | - | 0.02 | - | - | - | - | Upgrade
|
| Other Current Liabilities | - | 30.82 | 0.16 | 0.37 | 0.01 | 0.57 | Upgrade
|
| Total Current Liabilities | - | 30.84 | 0.16 | 0.37 | 62.67 | 5.38 | Upgrade
|
| Long-Term Debt | - | - | - | 0.9 | 0.83 | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | -0 | - | Upgrade
|
| Total Liabilities | - | 30.84 | 0.16 | 1.27 | 63.49 | 5.38 | Upgrade
|
| Common Stock | - | 66.07 | 66.07 | 66.07 | 66.07 | 66.07 | Upgrade
|
| Retained Earnings | - | -13.09 | -13.14 | -11.68 | -10.49 | -15.98 | Upgrade
|
| Comprehensive Income & Other | - | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 | Upgrade
|
| Shareholders' Equity | 53.29 | 53.8 | 53.74 | 55.2 | 56.39 | 50.9 | Upgrade
|
| Total Liabilities & Equity | - | 84.63 | 53.9 | 56.47 | 119.88 | 56.28 | Upgrade
|
| Total Debt | - | - | - | 0.9 | 0.83 | - | Upgrade
|
| Net Cash (Debt) | 0.24 | 0.22 | 0.21 | -0.76 | -0.7 | 0.19 | Upgrade
|
| Net Cash Growth | 49.06% | 5.21% | - | - | - | -23.13% | Upgrade
|
| Net Cash Per Share | 0.01 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | Upgrade
|
| Filing Date Shares Outstanding | 21.3 | 66.07 | 66.07 | 66.07 | 66.07 | 66.07 | Upgrade
|
| Total Common Shares Outstanding | 21.3 | 66.07 | 66.07 | 66.07 | 66.07 | 66.07 | Upgrade
|
| Working Capital | - | -30.57 | 0.07 | -0.23 | -0.37 | -5.19 | Upgrade
|
| Book Value Per Share | 1.26 | 0.81 | 0.81 | 0.84 | 0.85 | 0.77 | Upgrade
|
| Tangible Book Value | 53.29 | 53.8 | 53.74 | 55.2 | 56.39 | 50.9 | Upgrade
|
| Tangible Book Value Per Share | 1.26 | 0.81 | 0.81 | 0.84 | 0.85 | 0.77 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.